{"id":"zx-7101a-for-oral-suspension","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting HIF-1α, ZX-7101A aims to reduce tumor growth and angiogenesis. This mechanism is thought to be beneficial in treating various types of cancer.","oneSentence":"ZX-7101A is a small molecule that targets the HIF-1α pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:33.239Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07095257","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza","status":"RECRUITING","sponsor":"Nanjing Zenshine Pharmaceuticals","startDate":"2025-10-13","conditions":"Respiratory Viral Infection","enrollment":168},{"nctId":"NCT06669351","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza","status":"TERMINATED","sponsor":"Nanjing Zenshine Pharmaceuticals","startDate":"2024-10-31","conditions":"Respiratory Viral Infection","enrollment":98},{"nctId":"NCT06841926","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Relative Bioavailability of Metabolites in Healthy Chinese Adult Males","status":"COMPLETED","sponsor":"Nanjing Zenshine Pharmaceuticals","startDate":"2025-02-20","conditions":"Respiratory Viral Infection","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ZX-7101A for oral suspension","genericName":"ZX-7101A for oral suspension","companyName":"Nanjing Zenshine Pharmaceuticals","companyId":"nanjing-zenshine-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ZX-7101A is a small molecule that targets the HIF-1α pathway. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic renal cell carcinoma.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}